Barclays Begins Coverage on ANI Pharmaceuticals (NASDAQ:ANIP)

Investment analysts at Barclays began coverage on shares of ANI Pharmaceuticals (NASDAQ:ANIP) in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage set an “overweight” rating and a $100.00 price target on the specialty pharmaceutical company’s stock. Barclays‘s price target points to a potential upside of 21.91% from the company’s current price.

ANIP has been the subject of a number of other research reports. Weiss Ratings reissued a “buy (b-)” rating on shares of ANI Pharmaceuticals in a report on Monday, December 1st. Wall Street Zen upgraded shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 16th. HC Wainwright boosted their price target on ANI Pharmaceuticals from $93.00 to $121.00 and gave the company a “buy” rating in a research note on Wednesday, September 17th. Zacks Research raised ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 21st. Finally, Truist Financial raised their price objective on ANI Pharmaceuticals from $77.00 to $90.00 and gave the stock a “hold” rating in a research note on Thursday, October 9th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $102.14.

ANI Pharmaceuticals Stock Performance

ANIP opened at $82.03 on Tuesday. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.58 and a quick ratio of 2.04. The business has a fifty day simple moving average of $87.93 and a 200 day simple moving average of $80.37. ANI Pharmaceuticals has a 1 year low of $52.50 and a 1 year high of $99.50. The company has a market capitalization of $1.84 billion, a PE ratio of 50.33 and a beta of 0.48.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.74 by $0.30. The firm had revenue of $227.81 million for the quarter, compared to analysts’ expectations of $211.92 million. ANI Pharmaceuticals had a return on equity of 26.73% and a net margin of 4.91%.The company’s quarterly revenue was up 53.6% compared to the same quarter last year. During the same quarter last year, the business earned $1.34 EPS. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. Research analysts expect that ANI Pharmaceuticals will post 3.86 EPS for the current year.

Insiders Place Their Bets

In other news, SVP Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock in a transaction on Friday, September 19th. The stock was sold at an average price of $98.04, for a total value of $98,040.00. Following the transaction, the senior vice president owned 60,186 shares in the company, valued at approximately $5,900,635.44. This trade represents a 1.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Meredith Cook sold 400 shares of the business’s stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $87.27, for a total value of $34,908.00. Following the transaction, the vice president directly owned 75,274 shares of the company’s stock, valued at $6,569,161.98. This trade represents a 0.53% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 27,379 shares of company stock valued at $2,417,761 over the last three months. 11.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ANIP. Tudor Investment Corp ET AL acquired a new position in ANI Pharmaceuticals during the third quarter worth about $1,085,000. Penn Capital Management Company LLC boosted its stake in shares of ANI Pharmaceuticals by 6.5% in the 3rd quarter. Penn Capital Management Company LLC now owns 6,364 shares of the specialty pharmaceutical company’s stock valued at $583,000 after purchasing an additional 387 shares in the last quarter. Danske Bank A S bought a new stake in shares of ANI Pharmaceuticals during the 3rd quarter valued at approximately $864,000. Advisory Services Network LLC acquired a new position in ANI Pharmaceuticals during the 3rd quarter worth approximately $366,000. Finally, CANADA LIFE ASSURANCE Co increased its position in ANI Pharmaceuticals by 3.3% during the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 20,042 shares of the specialty pharmaceutical company’s stock worth $1,841,000 after purchasing an additional 634 shares in the last quarter. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.